Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4415—Pyridoxine, i.e. Vitamin B6
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
  • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

• This invention relates to novel pharmaceutical compositions, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper- prohferative disorders, such as cancer, either as a sole agent or in combination with other therapies
• Diarylureas are a class of serine- threonine kinase inhibitors as well as tyrosine kinase inhibitors known in the art
• the following publications illustrate their utility as active ingredient in pharmaceutical compositions for the treatment of hyper-prohferative diseases, such as cancer
• the diphenyl urea of Formula I also referred as 4 ⁇ 4-[3-(4-chloro-3-t ⁇ fluoromethylphenyl)-ureido]-3-fluorophenoxy ⁇ -py ⁇ dine-2- carboxyhc acid methyl amide is a potent inhibitor of raf, VEGFR-2, p3S, and PDGFR kinases These enzymes are all molecular targets of interest for the treatment of hyper- proliferative diseases, including cancer Therefore, the compound of Formula I will be used as medicine for the treatment of the above mentioned diseases
• the preferred route of drug administration is through the oral cavity This route provides the greatest comfort and convenience of dosing
• the bioavailability achieved after oral administration is a measure for the potential usefulness of an oral dosage form of a drug
• Bioavailability after oral application depends on several factors, such as solubility of the active in aqueous media, dose strength, dissolution of the dosage form, absorption throughout the gastrointestinal tract and first pass effect Therefore solid pharmaceutical compositions for oral application containing the compound of Formula I, which result in improved dissolution, absorption and exposure in mammals, improved tnter-patient variability, and overall improved efficacv m the clinic are desired
• the compound of Formula I does not only refer to 4 f 4-[3-(4-chloro-3-t ⁇ fluoromethylphenyl)-ureido]-3-f!uorophenoxy ⁇ - pyndine-2-carboxylic acid methyl amide as depicted in Formula I, but also refers to its solvates, hydrates, pharmaceutically acceptable salts, or a combination thereof
• the present invention pertains to
• novel pharmaceutical compositions containing the compound of Formula I in the form of a solid dispersion which includes solid solutions, glass solutions, glass suspensions, amorphous precipitations in a crystalline earner, eutectics or monotecics, compound or complex formation and combinations thereof
• processes for preparing these novel pharmaceutical compositions in) the use of these compositions for the treatment of hyper-proliferative diseases, such as cancer, either as a sole agent, or in combination with other therapies
• solid dispersions solid solutions, glass solutions, glass suspensions, amorphous precipitations in a crystalline earner, eutectics or monotecics, compound or complex formation and combinations thereof
• solid dispersion A pharmaceutical composition according to thus invention comp ⁇ ses of a solid dispersion comprising at least the compound of Formula I and a pharmaceutically acceptable matnx
• matnx. ' or “matn ⁇ agents” as used herein refers to both polymeric excipients, non-polyme ⁇ c excipients and combinations thereof capable of dissolving or dispersing the compound of formula I
• Axi aspect of the invention of particular interest is a pharmaceutical composition
• a pharmaceutical composition comprising a solid dispersion, wherein the matrix comprises a pharmaceutical]) acceptable polymer, such as, for example, polyvinylpyrrolidone, vinylpyrrolidone/ vinylacetate copolymer, crospovidone, polyalkylene glycol (e g polyethylene glycol), polyethylenoxide, poloxamer, hydroxyalkyl cellulose (e g hydroxypropyl cellulose;, hydroxyalkyl methyl cellulose (e g hydroxypropyl methyl cellulose), carboxymethyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, cellulose succinates (e g cellulose acetate succinate and hydroxypropyl methyl cellulose acetate succinate), cellulose phthalates (e g cellulose acetate phthalate and hydroxypropyl methyl cellulose phthalate), poly ⁇ nethacrylates (e g Eudragit ® types),
• Another aspect of the invention is a pharmaceutical composition
• a pharmaceutical composition comprising a solid dispersion, wherein the matnx comprises a sugar and/or sugar alcohol and- or cyclodextnn, such as, for example sucrose, lactose, fructose, maltose, raffinose, sorbitol, lactitol, mannitol, maltitol, eryth ⁇ tol, threitol, adonitol, arabitol, xylitol, dulcitol, inositol, trehalose, isomalt, inulin, maltodext ⁇ n, ⁇ -cyclodextnn, hydroxypropyl- ⁇ -cyclodextnn, sulfobutyl ether cyclodextnn or combinations thereof
• excipients that are useful in the formation of the matnx of the solid dispersion include, but are not limited to alcohols, organic acids, organic bases salts, ammo acids, peptides, phospholipids, lipids (e g mono-, di- and t ⁇ glycendes), fatty acids, fatty alcohols, waxes, fatty acid esters, polyoxyethy lene sorbitan fatty acid esters, polyglycohzed glycendes, sucrose esters, urea and combinations thereo f
• the solid dispersion of the compound of Formula I in the matnx may contain certain additional pharmaceutical acceptable ingredients, such as earners, surfactants, fillers, disintegrants, adsorbants, recrystalhzation inhibitors, plasticizers, fluxing agents, defoamers, antioxidants, detackifier, pH-modifiers, glidants and lubricants,
• additional pharmaceutical acceptable ingredients such as earners, surfactants, fillers, disintegrants, adsorbants, recrystalhzation inhibitors, plasticizers, fluxing agents, defoamers, antioxidants, detackifier, pH-modifiers, glidants and lubricants
• a earner according to this invention is an excipient, which becomes loaded with a mixture, compnsing of at least the matnx agent and the compound of this invention, dunng the manufactiinng process of the solid dispersion, for example by hot melt extrusion, hot melt coating, pnlhng, congealing, solvent evaporation processes (e g layenng, coating, granulation), and thus becomes an integral part of the solid dispersion
• the matnx comprises a water soluble polymer
• Ln another preferred embodiment at least one from the group of polyvinylpyrrolidone, copovidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol and polyethylene oxide is used as matnx agent in the solid dispersion
• An embodiment of particular interest compnses the compound of Formula I (calculated as solvent-free base) and polyvinylpyrrolidone in a weight ratio of 1 0 5 to 1 20
• Another preferred embodiment compnses hydroxypropyl cellulose as matnx agent
• An embodiment of particular interest comprises the compound of Formula I (calculated as solvent-free base) and hydro ⁇ ypropyl cellulose in a weight ratio of 1 0 5 to 1 20
• Another aspect of the invention of particular interest are solid dispersions containing croscarmellose sodium, sodium starch glycolate, crospovidone, low substituted hydroxypropyl cellulose (L-HPC), starch, microcrystallme cellulose or a combination thereof as earner or disintegrant
• the solid dispersion comprises polyv inylpyrrolidone and croscarmellose sodium
• the solid dispersion comprises polyvinylpyrrolidone and sodium starch glycolate
• the solid dispersion comprises polyvinylpyrroli ⁇ done, croscarmellose sodium and microcrystalline cellulose
• the solid dispersion comprises hydroxypropyl cellulose and croscarmellose sodium
• the solid dispersion comprises hydroxypropyl cellulose and at least one excipient, which is a sugar, sugar alcohol, cyclodextnn
• the solid dispersion of the invention is prepared according to methods known to the art for the manufacture of solid dispersions, such as fusion/melt technology, hot melt extrusion, hot melt coating, p ⁇ lhng, congealing, solvent evaporation (e g freeze drying, spray drying, vacuum drying, layering of powders, granules or pellets and fluid bed granulation), coprecipitation, supercritical fluid technology and electrostatic spinning method Hot melt extrusion or solvent evaporation techniques are preferred processes for preparation of solid dispersion formulations of this invention
• a solvent suitable for manufacture of solid dispersions by solvent evaporation processes such as spray-drying, layering and fluid-bed granulation can be any compound, wherein the compound of Formula I can be dissolved
• Preferred solv ents include alcohols (e g methanol, ethanol, n-propanol, isopropanol, and butanol), ketones (e g acetone, methyl ethyl ketone and methyl isobutyl ketone), esters (e g ethyl acetate and propyl acetate) and ⁇ anous other solvents such as acetonit ⁇ le, methylene chloride, choroform, hexane, toluene, tetrahydrofurane, cyclic ethers, and 1 , 1 , 1 -tnchloroethane
• Lower volatility solvents, such as dimethyl acetamide or dimethylsulfoxide can also be used Mixtures of solvents,
• the solvent used for manufacture of the solid dispersion comprises methanol, ethanol, n-propanol, isopropanol or acetone
• An aspect of the invention of particular interest is a composition, wherein the solid dispersion is substantially homogeneous
• An aspect of the invention of particular interest is a pharmaceutical composition, in which the compound of Formula I is substantially amorphous
• This pharmaceutical composition will be utilized to achieve the desired pharmacological effect by oral administration to a patient in need thereof, and will be advantageous to a conventional formulation in terms of drug release, bioavailability, inter-patient variability and/or efficacy m mammals
• a patient, for the purpose of this invention is a mammal, including a human, in need of treatment for the particular condition or disease, including prophylactic treatment
• the solid dispersion desc ⁇ bed herein can be formulated into solid or hquid preparations such as powder, granules, pellets, tablets, capsules, dragees, chewable tablets, effervescent tablets, dispersible tablets, troches, lozenges, melts, solutions, suspensions, or emulsions, and may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions
• the solid dispersion may be compounded with conventional excipients, for example binders, fillers, lubricants, disintegrants, solvents, surfactants, emulsifiers, thickeners and stabilizers, ghdants and lubricants, coating mate ⁇ als as well as sweeteners, flavoring and coloring agents
• the oral formulation of the compound of Formula I refers to a wide range of dosages such as 1 mg, 10 mg, 100 mg, or even 1 g daily dosing and beyond This would be accomplished, for example, by modifying the composition and size of the tablet or capsule, and/or by administering multiple tablets or capsules per day to the patient in need thereof Alternatively, the solid dispersion formulation may also be dosed in forms such as powders, granules, chewable, effervescent or dispersible tablets, or by dispersions of any adequate solid formulation in a suitable liquid prior to use, for example if the optimal dose regimen was no longer consistent with a feasible tablet or capsule size
• the present invention also relates to a method for using a new oral pharmaceutical composition of the compound of Formula I to treat mammalian hyper-prohferative disorders, including cancer
• This method comprises administering the pharmaceutical composition in the form of a solid dispersion to a mammal in need thereof, including a human, an amount which is effective to treat the disorder
• the term "hyper- prohferative disorders" and/or “cancer” not only refers to solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases, but also includes lymphomas, sarcomas, and leukemias
• breast cancer include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ
• cancers of the respiratory tract include, but are not limited to small-cell and non-small-cell lung carcinoma, as well as bronchjal a
• brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and DCebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor
• Tumors of the male reproductive organs include, but are not limited to prostate and testicular cancer
• Tumors of the female reproductiv e organs include, but are not limited to endometrial, cervical, ova ⁇ an, vaginal, and vulvar cancer, as well as sarcoma of the uterus
• Tumors of the digestive tract include, but are not limited to anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small intestine, and salivary gland cancers
• Tumors of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, and urethral cancers
• Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma
• liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma
• Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi 's sarcoma, malignant melanoma. Merkel cell skin cancer, and non-melanoma skin cancer
• Head-and-neck cancers include, but are not limited to laryngeal / hypopharyngeal / nasopharyngeal / oropharyngeal cancer, and lip and oral cavity cancer
• Lymphomas include, but are not limited to AJDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgki ⁇ 's disease, and lymphoma of the central nervous system.
• Sarcomas include, but are not limited to sarcoma of the soft tissue, fibrosarcoma, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma
• Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia
• the total amount of the active ingredient (compound of Formula I) to be administered via the oral route using the pharmaceutical composition of the present invention will generally range from about 0 01 mg/kg to about 50 mg/kg body weight per day Based upon standard laboratory techniques known to evaluate compounds useful for the treatment of hyper-proliferative disorders, by standard toxicity tests and by standard pharmacological assays for the determination of treatment of the conditions identified above in mammals, and by comparison of these results with the results of known medicaments that are used to treat these conditions, the effective dosage of the pharmaceutical compositions of this invention can readily be determined by those skilled in the art
• the amount of the administered active ingredient can vary widely according to such considerations as the particular compound and dosage urut employed, the mode and time of administration, the pe ⁇ od of treatment, the age, sex, and general condition of the patient treated, the nature and extent of the condition treated, the rate of drug metabolism and excretion, the potential drug combinations and drug-drug interactions, and the like
• compositions of this invention can be administered as the sole agent or in combination with one or more other therapies where the combination causes no unacceptable adverse effects
• they can be combined with cytotoxic agents, signal transduction inhibitors, or with other anti-cancer agents or therapies, as well as with admixtures and combinations thereof
• the pharmaceutical compositions of the present invention can be combined with cytotoxic anti-cancer agents
• cytotoxic anti-cancer agents examples of such agents can be found in the 1 1 th Edition of the Merck Index ( 1996) These agents include, by no way of limitation, asparaginase, bleomycin, carboplatm, carmustme, chlorambucil, cisplaUn, colaspase, cyclophosphamide, cytarabine, dacarbazine, dacttnomycin, ⁇ aunorubicin, doxorubicin (adnamycine), epirubicin, etoposide, 5-fluorourac ⁇ l, hexamethylmelamine,
• cytotoxic drugs suitable for use with the pharmaceutical compositions of the invention include, but aie not limited to, those compounds acknowledged to be used in the treatment of neoplastic diseases in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Ninth Edition, 1996, McGraw-Hill) These agents include, by no way of limitation, aminoglutethimide, L-asparaginase, azathiop ⁇ ne, 5-azacytidtne clad ⁇ bine, busulfan, diethylstilbestrol, 2', T- difluorodeoxycytidine, docetaxel, erythrohydroxynonyladenine, ethinyl estradiol, 5- fluorodeoxyu ⁇ dine, 5-fIuorodeoxyundine monophosphate, fludarabine phosphate, fluoxymesterone, flutamide, hydroxyprogesterone caproate, idaaibicin, interferon, medroxyprogesterone acetate
• cytotoxic anti-cancer agents suitable for use in combination with the compositions of the invention also include newly discovered cytotoxic principles such as oxahplatin, gem ⁇ tabine, capecitabme, epothilone and its natural or synthetic de ⁇ vatives, temozolomide (Qui ⁇ n et al , J Clin Oncology 2003, -?/(4), 646-65 1), tositumomab (Bex.xar), trabedectm (Vidal et al , Proceedings of the American Society or Clinical Oncology 2004, 23, abstract 3181), and the inhibitors of the kinesin spindle protein Eg5 (Wood et al , Curr Opin Pharmacol 2001 , /, 370-377)
• cytotoxic principles such as oxahplatin, gem ⁇ tabine, capecitabme, epothilone and its natural or synthetic de ⁇ vatives, temozolomide (Qui ⁇ n et al
• the pharmaceutical compositions of the present invention can be combined with other signal transduction inhibitors
• signal transduction inhibitors which target the EGFR familv, such as EGFR, HER-2, and HER-4 (Raymond et al , Drugs 2000, 60 (Suppl [ ), 15-23 , Hara ⁇ et al , Oncogene 2000, 19 (53), 6102-61 14), and their respective ligands
• Examples of such agents include, by no way of limitation, antibody therapies such as Herceptm (trastuzumab), Erbitux (cetuximab), and pertuzumab
• therapies also include, by no way of limitation, small-molecule kinase inhibitors such as ZD- 1839 / Iressa (Baselga et al , Drugs 2000, 60 (Suppl 1 ), 33-40), OSI-774 / Tarceva (Pollack et al J Pharm Exp Ther 1999, 291(1), 7
• HKI-272 (Rabmdran et al , Cancer Res 2004, 64, 3958-3965), and EKB-569 (Greenberger et al , 11 th NC1-EORTC-A.4CR Symposium on New Drugs in Cancer Therapy, Amsterdam, November 7-10, 2000, abstract 388)
• compositions of the present invention can be combined with other signal transduction inhibitors targeting receptor kinases of the spht-kinase domain families (VEGFR, FGFR, PDGFR, flt-3, c-kit, c-fms, and the like), and their respective ligands
• agents include, by no way of limitation, antibodies such as Avastin (bevacizumab)
• agents also include, by no way of limitation, small-molecule inhibitors such as STI-571 / Gleevec (Zvelebil, Curr Opin Oncol , Endocr Metab Invest Drugs 2000, 2( 1), 74-82), PTK-787 (Wood et al , Cancer Res 2000, 60(S), 2178-2189), SU-1 1248 (Demetn et al , Proceedings of the American Society for Clinical Oncology 2004, 23, abstract 3001), ZD-6474 (Hennequm et al , 92 nd A.4CR
• compositions of the present invention can be combined with inhibitors of aurora kinases (Mortlock et al , Curr Topics Med C hem 2005, 5, 199) These include, by no way of limitation, VX-680 (Hamngton et al , Nature Med 2004, 10, 262), and PHA-6S0632 (Fancelli et al , Proceedings of the American Association of Cancer Research 2005, 46, abstract LB-1 13)
• compositions of the present invention can be combined with inhibitors of bcr-abl and/or src
• inhibitors of bcr-abl and/or src include, by no way of limitation, AZD-0530 (Gallagher et al , Proceedings of the American Association of Cancer Research 2005, 46, abstract 3972), AMN- 107 and BMS-354825 (O'Hare et al , Cancer Res 2005, 65( 1 1), 4500)
• compositions of the present invention can be combined with inhibitors of the Raf/MEK/ERK transduction pathway (Avruch et al , Recent Prog Horm Res 2001, 56, 127- 155), or the PKB (akt) pathway (Lawlor et al . J Cell Sa 2001 , 114, 2903-2910)
• inhibitors of the Raf/MEK/ERK transduction pathway include, by no way of limitation, PD- 325901 (Sebolt-Leopold et al , Proceedings of the American Association of Cancer Research 2004, 45, abstract 4003), and ARRY- 142886 (Wallace et a! , Proceedings of the American Association of Cancer Research 2004, 45, abstract 3891 )
• the pharmaceutical compositions of the present invention can be combined with inhibitors of histone deacetylase
• examples of such agents include, by no way of limitation, suberoylarulide hydroxamic acid (SAHA), LAQ-824 (Ottmann et al , Proceedings of the American Society for Clinical Oncology 2004, 23, abstract 3024), LBH-589 (Beck et al , Proceedings of the American Society for Clinical Oncology 2004, 23, abstract 3025), MS-275 (Ryan et al , Proceedings of the American Association of Cancer Research 2004, 45, abstract 2452), and FR-901228 (Piekarz et al , Proceedings of the American Society for Clinical Oncology 2004, 23, abstract 3028)
• the pharmaceutical compositions of the present invention can be combined with other anti-cancer agents such as proteasome inhibitors, and m-TOR inhibitors These include, by no way of limitation, bortezomib (Mackay et al , Proceedings of the American Society for Clinical Oncology 2004, 23, Abstract 3
• cytotoxic and/or cytostatic anti-cancer agents in combination with the pharmaceutical compositions of the present invention will serve to
• Example 1 A synthetic preparation of the compound used in this invention is described in Example 1 Representative salts of the compound of Example 1 are described in Examples 2, 3, and 4 Novel solid dispersion formulations of the compound of Formula I are desc ⁇ bed in Example 5 to 20 The examples will serve to further illustrate the invention without limiting it
• Example 2 The compound of Example 1 as a free base (2 25 g) was dissolved in ethanol ( 100 mL) and a stock solution of methanesulfonic acid (excess) was added The solution was then concentrated in vacuo to afford a yellow oil Ethanol was added and concentration repeated, affording 2 41 g of off-white solids
• the crude salt was dissolved in hot ethanol (- 125 mL) and then cooled slowly to crystallize After reaching room temperature, the flask was placed in a freezer overnight The colorless crystalline material was collected by suction filtration, the filter cake was w ashed w ith ethanol, then hexane and air-d ⁇ ed, to afford 2 05 g of material, which was d ⁇ ed in a vacuum oven at 60 0 C overnight Melting point 23 1 0 C Elemental analysis
• Example 1 The compound of Example 1 as a free base (2 25 g) was suspended in ethanol (50 mL) and benzensulfonic acid (0 737 g) in ethanol (50 mL) was added The mixture was heated with vigorous stir ⁇ ng All solid material dissolved to give a reddish solution The solution was allowed to cool to room temperature and the flask scratched Crystal formation was slow, some seeds were found, added to solution and placed in freezer overnight Grayish-tan solids had formed in the flask, the materia! was broken up & collected by suction filtration The solids were washed with ethanol, then hexane and air-d ⁇ ed Weighed product 2 05 g, 69% yield Melting point 213 0 C Elemental Analysis
• Example 5 Preparatioo of a 1+4 solid dispersion of 4 ⁇ 4-(3-(4-chloro-3- tnfluoromethY lphenyl)-ureidoJ-3-fluorophenoxy ⁇ -pyridine-2-carboxylic acid methyl amide with polyvinylpyrrolidone.
• Example 1 In an uncapped vial, one part of the compound of Example 1 as a free base was mixed with four parts polyvinylpyrrolidone (PVP-25 / Kolhdon' 5 25), and dissolved in a sufficient amount of a 1 1 mixture of acetone and ethanol, until all powders are in solution The uncapped vial was placed into a vacuum oven set at 4O 0 C, and let dry for at least 24-48 hours.
• PVP-25 / Kolhdon' 5 25 polyvinylpyrrolidone
• Example 6 Preparation of a 1+3 solid dispersion of 4 ⁇ 4-[3-(4-ch!oro-3- tri ⁇ uoromethylphenyl)-ureido]-3-lluorophenoxy ⁇ -pyridine-2-carboxylic acid methyl amide with polyvinylpyrrolidone.
• Example 7 Preparation of a 1+7 solid dispersion of 4 ⁇ 4-[3-(4-chloro-3- trifluoromethylphenyl)-ureido]-3-fIuorophenoxy ⁇ -pyridine-2-carboxylic acid methyl amide with polyvinylpyrrolidone.
• Example 8 Solid dispersion of 4 ⁇ 4-[3-(4-chloro-3-trifluoromethylpheny
• Example 9 Solid dispersion of 4 ⁇ 4-[3-(4-chloro-3-trifluoromethylphenvl)- ureido]-3-fluorophenovy ⁇ -pyridine-2-carboxylic acid methyl amide with PVP and croscarmellose sodium.
• a solution of 0 4 kg of the of the compound of Formula I as base and 1 2 kg of P VP 25 in a mixture of 6 4 kg acetone and I 6 kg ethanol was prepared Using a fluidized bed vacuum granulator this solution was sprayed onto a powder bed of 1 6 kg croscarmellose sodium at a temperature of 60-70 0 C After drying the product was sieved ( 1 mm)
• the granulate can be used as it is or it can be further formulated for example to sachet, capsule or tablet formulations
• Example 10 Solid dispersion of 4 ⁇ 4-[3-(4-chloro-3-trifluoromethylphe ⁇ yl)- ureido]-3-fluorophenoxy ⁇ -py ⁇ dine-2-carboxylic acid methyl amide with PVP and sodium starch glycolate.
• This mate ⁇ al was prepared in a similar way as described in Example 9, except that the solution is sprayed onto a powder bed of 1 6 kg sodium starch gycolate Type A (Explotab ® )
• Example 11 Solid dispersion of 4 ⁇ 4-[3-(4-chloro-3-trifluoromethylphenyl)- ureido]-3-fiuoropheno ⁇ y ⁇ -pyridine-2-carboxy!ic acid methyl amide with PVP and croscarmellose sodium .
• This mate ⁇ al was prepared in a similar way as described in Example 1 1 , except that the solution was sprayed onto a powder bed consisting of 1 kg croscarmellose sodium and 1 kg microcrystalline cellulose
• Example 13 Solid dispersio ⁇ of 4 ⁇ 4-[3-(4-ch]oro-3-trifluoromethylphenyI)- ureido]-3-fiuorophe ⁇ oxy ⁇ -py ridine-2-carboxylic acid meth> l amide with HPC-SL and croscarmellose sodium .
• Example 14 Solid dispersion of 4 ⁇ 4-(3-(4-chloro-3-trifluoromethylpheuyl)- ureido]-3-fiuorophenoxy ⁇ -pyridine-2-carboxy lic acid methyl amide with HPC-L and croscarmellose sodium .
• a solution of 0 4 kg of the of the compound of Formula I as base and 1 6 kg of HPC-L in 28 kg acetone was prepared Using a fluidized bed vacuum granulator this solution was sprayed onto a powder bed of 2 kg croscarmellose sodium at a temperature of 40-60 0 C After drying the product was sieved ( 1 mm)
• the granulate can be used as it is or it can be further formulated for example to sachet, capsule or tablet formulations
• Example 15 Tablets containing a solid dispersion of 4 ⁇ 4-[3-(4-chloro-3- trifluoromethylphenyl)-ureido
• Example 1 1 The granulate of Example 1 1 was roller compacted and screened 3 and 1 mm Subsequently the compacted granulate was blended with 0 54 kg croscarmellose sodium, 24 g colloidal anhydrous silica and 36 g magnesium stearate This ready-to- press blend was compressed on a rotary tablet press to tablets containing 20, 50 an 100 mg of the compound of Formula I The tablets may be film-coated for light protection.
• Example 16 Tablets containing a solid dispersion of 4 ⁇ 4-[3-(4-chloro-3- trifluoromethylpnenyl)-Lireido]-3-fluoropheno ⁇ y ⁇ -pyridine-2-carboxylic acid methyl amide
• Example 12 The granulate of Example 12 was roller compacted and screened 3 and I mm Subsequently the compacted granulate was blended with 0 54 kg croscarmellose sodium, 24 g colloidal anhydrous silica and 36 g magnesium stearate This ready-to- press blend was compressed on a rotary tablet press to tablets containing 20, 50 an 100 mg of the compound of Formula I The tablets may be film-coated for light protection
• Example 17 Tablets containing a solid dispersion of 4 ⁇ 4-[3-(4-cliloro-3- trifluorornethylphenyl)-ureido]-3-fluoropheno ⁇ y ⁇ -pyridine-2-carboxylic acid methyl amide
• Example 19 Comparison of the oral bioavailability of several conventional formulations of the compound of Example I , and the new pharmaceutical composition of Example 5.
• Example 5 A single dose of the compounds of Examples I , 2, 3, 4, and 5 was administered to each of three fasted male Wistar rats (220-250 g; 6-8 weeks old) orally Compounds of Examples 1 -4 were administered by oral gavage in the formulation desc ⁇ bed in Table 1 .
• the solid dispersion of Example 5 ( 1.25 mg drug substance in 5 mg PVP-25) was administered in size 9 capsules One capsule was administered per rat.
• Approximately 0.4 mL of whole blood was collected via an indwelling jugular catheter at: 0.25, 0.5, 1 , 2, 4, 7, 24, and 48 h post-dose. The blood samples were cent ⁇ fuged (approx. 5 min.) in order to obtain plasma which was then transferred to the appropriately labeled vials and stored frozen (-20 0 C) until analysis for parent drug.
• Plasma samples were analyzed via LC/MS/MS for parent drug concentrations and pharmacokinetic parameters were calculated using Watson LlMS.
• Table 1 Comparative oral bioavailabilities in the rat for different formulations of the compound of Formula I
• the dose of 5 mg/kg of the pharmaceutical composition of Example 5 means 5 mg of drug substance (compound of Example 1 ) per kg of body weight.
• the relative bioavailabilities in the rat are calculated from the data of an intravenous bolus dose of 2 mg/kg in the same strain of rats, using a solution of the active in a Cremophor RH40: ethanol. water ( 12.5 • 12.5 :75) vehicle.
• the pharmaceutical composition based on a 1 +4 solid dispersion of the compound of this inv ention with polyviny lpyrrolidone provides an improved absorption and oral exposure in the rat, compared to two conventional formulations of the free base, and three conventional formulations of pharmaceutically acceptable salts of the compound of Formula I.
• Example 20 Comparison of the exposure of a new pharmaceutical composition and a conventional formulation of the compound of Formula I
• the conventional formulation was a suspension o f the micronized compound o f formula I as base in an aqueous 0 5% tylos ⁇ solution
• the novel formulation was the solid dispersion granulate of Example 1 1 , which was suspended in water p ⁇ or to administration
• Example 1 1 containing 10% of the compound of this invention, an amount of 20, 100 and 500 mg granulate/kg body weight (equivalent to doses of 2, 10 and 50 mg/kg respectively) was administered in 5 mL water/kg body weight
• Plasma samples were analyzed v ia LC/MSMS for parent drug concentrations and pharmacokinetic parameters were calculated. The results are presented in Table 2
• the AUC and c max data reveal significant differences for the exposure of the active after oral application of the conventional and the novel formulation the exposure obtained after administration of the new composition of this invention is significantly higher compared to the exposure of the conventional suspension formulation
• AUC is increased by a factor of 2 5 to 3 5
• c max is increased by factor 2 9 respectively 4 8 for the novel composition of this invention
• the increase is even more pronounced both AUC and c max of the novel formulation are 5 times higher than for the conventional suspension
• this new type of pharmaceutical composition comprising a solid dispersion of the compound of Formula I, will result in improved absorption and exposure, reduced inter-patient variability, and overall superior efficacy for the treatment of hyper-prohferative disorders, including cancer

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Pyridine Compounds (AREA)
• Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Priority Applications (25)

Applications Claiming Priority (2)

Publications (1)

Family

ID=35517032

Family Applications (1)

Country Status (41)

Cited By (28)

Families Citing this family (23)

Citations (4)

Family Cites Families (21)

• 2005
  • 2005-08-25 MY MYPI20054000A patent/MY191349A/en unknown
  • 2005-08-26 HN HN2005000484A patent/HN2005000484A/es unknown
  • 2005-08-26 UY UY29086A patent/UY29086A1/es not_active Application Discontinuation
  • 2005-08-26 GT GT200500230A patent/GT200500230A/es unknown
  • 2005-08-26 AR ARP050103568A patent/AR050616A1/es not_active Application Discontinuation
  • 2005-08-26 PE PE2005000984A patent/PE20060505A1/es active IP Right Grant
  • 2005-08-26 TW TW094129395A patent/TWI369987B/zh not_active IP Right Cessation
  • 2005-08-26 US US11/212,109 patent/US20060058358A1/en not_active Abandoned
  • 2005-08-26 PE PE2010000029A patent/PE20100432A1/es active IP Right Grant
  • 2005-08-29 SI SI200532037T patent/SI1793824T1/sl unknown
  • 2005-08-29 AU AU2005279996A patent/AU2005279996A1/en not_active Abandoned
  • 2005-08-29 UA UAA200703203A patent/UA92472C2/ru unknown
  • 2005-08-29 BR BRPI0514715-8A patent/BRPI0514715B1/pt active IP Right Grant
  • 2005-08-29 HU HUE05792486A patent/HUE026654T2/en unknown
  • 2005-08-29 MX MX2007002397A patent/MX2007002397A/es active IP Right Grant
  • 2005-08-29 HR HRP20160156TT patent/HRP20160156T1/hr unknown
  • 2005-08-29 PL PL05792486T patent/PL1793824T3/pl unknown
  • 2005-08-29 CA CA2578438A patent/CA2578438C/en not_active Expired - Lifetime
  • 2005-08-29 CN CN2012102807209A patent/CN102885813A/zh active Pending
  • 2005-08-29 EP EP05792486.2A patent/EP1793824B1/en not_active Revoked
  • 2005-08-29 WO PCT/US2005/030541 patent/WO2006026500A1/en not_active Ceased
  • 2005-08-29 NZ NZ553557A patent/NZ553557A/en not_active IP Right Cessation
  • 2005-08-29 DK DK05792486.2T patent/DK1793824T3/en active
  • 2005-08-29 CN CNA2005800371513A patent/CN101287463A/zh active Pending
  • 2005-08-29 JP JP2007533489A patent/JP5017115B2/ja not_active Expired - Lifetime
  • 2005-08-29 EP EP13151040.6A patent/EP2589384A1/en not_active Withdrawn
  • 2005-08-29 RS RS20160039A patent/RS54580B1/sr unknown
  • 2005-08-29 PT PT57924862T patent/PT1793824E/pt unknown
  • 2005-08-29 ES ES05792486.2T patent/ES2561618T3/es not_active Expired - Lifetime
  • 2005-08-29 EA EA200700501A patent/EA010832B1/ru unknown
  • 2005-08-29 ME MEP-358/08A patent/MEP35808A/xx unknown
  • 2005-08-29 ME MEP-2008-358A patent/ME00152B/me unknown
  • 2005-08-29 KR KR1020077006801A patent/KR101336737B1/ko not_active Expired - Lifetime
• 2007
  • 2007-02-26 TN TNP2007000076A patent/TNSN07076A1/en unknown
  • 2007-02-27 NI NI200700064A patent/NI200700064A/es unknown
  • 2007-02-27 IL IL181590A patent/IL181590A/en active IP Right Grant
  • 2007-03-05 EC EC2007007299A patent/ECSP077299A/es unknown
  • 2007-03-07 CR CR8980A patent/CR8980A/es unknown
  • 2007-03-22 ZA ZA200702392A patent/ZA200702392B/xx unknown
  • 2007-03-22 MA MA29767A patent/MA28911B1/fr unknown
  • 2007-03-26 NO NO20071584A patent/NO343937B1/no active Protection Beyond IP Right Term
• 2010
  • 2010-12-20 CL CL2010001484A patent/CL2010001484A1/es unknown
• 2016
  • 2016-03-22 LT LTPA2016008C patent/LTC1793824I2/lt unknown
• 2017
  • 2017-01-27 US US15/417,469 patent/US20170165243A1/en not_active Abandoned
  • 2017-11-08 LU LU00047C patent/LUC00047I2/fr unknown
  • 2017-11-09 CY CY2017038C patent/CY2017038I1/el unknown
  • 2017-11-21 HU HUS1700047C patent/HUS1700047I1/hu unknown
• 2019
  • 2019-08-05 NO NO2019033C patent/NO2019033I1/no unknown

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events